CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $8.3571.

Several brokerages recently issued reports on CAMP. Leerink Partners increased their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. Zacks Research lowered CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday. Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Rodman & Renshaw assumed coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price target for the company. Finally, JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th.

Hedge Funds Weigh In On CAMP4 Therapeutics

Several hedge funds have recently bought and sold shares of the business. Vivo Capital LLC acquired a new position in CAMP4 Therapeutics during the third quarter worth $11,765,000. Balyasny Asset Management L.P. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter worth about $14,938,000. Janus Henderson Group PLC lifted its position in shares of CAMP4 Therapeutics by 35.9% in the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock worth $38,807,000 after buying an additional 1,666,666 shares during the last quarter. SummitTX Capital L.P. bought a new stake in shares of CAMP4 Therapeutics during the 1st quarter worth about $1,497,000. Finally, EcoR1 Capital LLC bought a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth about $1,992,000.

CAMP4 Therapeutics Stock Down 7.4%

CAMP stock opened at $3.90 on Friday. CAMP4 Therapeutics has a 12-month low of $1.32 and a 12-month high of $7.75. The company has a market cap of $202.53 million, a price-to-earnings ratio of -1.65 and a beta of 0.10. The company has a 50 day moving average of $4.28 and a two-hundred day moving average of $4.56.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. The company had revenue of $1.29 million for the quarter. On average, research analysts anticipate that CAMP4 Therapeutics will post -0.84 EPS for the current year.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.